Targeted therapy for NSCLC: ALK inhibition

Rachel Pearson; Jill M Kolesar

doi:10.1177/1078155211417477

Back

Targeted therapy for NSCLC: ALK inhibition

Journal article

Peer reviewed

Targeted therapy for NSCLC: ALK inhibition

Rachel Pearson and Jill M Kolesar

Journal of oncology pharmacy practice, Vol.18(2), pp.271-274

06/2012

DOI: 10.1177/1078155211417477

PMID: 21844131

View Online

Abstract

The purpose of this review article is to describe the emerging data of ALK receptor tyrosine kinaase inhibitors in ALK mutation positive NSCLC. ALK mutations have been identified in approximately 2.4-13% of patients with NSCLC, occurring more frequently in adenocarcinomas and never and light smokers. Crizotinib is an oral ATP-competitive selective inhibitor of the ALK and MET tyrosine kinases that inhibits tyrosine phosphorylation of activated ALK at nanomolar concentrations. A phase II study demonstrated an overall response rate of 57% (95% CI, 46 to 68), with the most common toxicity grade I fatigue and visual disturbances. Elevations in lever function tests were also reported. The ALK receptor tyrosine kinase inhibitor crizotinib may be an effective therapy in ALK mutated NSCLC and is currently being compared to standard chemotherapy for advanced or metastatic NSCLC.

Animals

Antineoplastic Agents - administration & dosage

Carcinoma, Non-Small-Cell Lung - drug therapy

Carcinoma, Non-Small-Cell Lung - enzymology

Carcinoma, Non-Small-Cell Lung - genetics

Clinical Trials, Phase II as Topic - methods

Drug Delivery Systems - methods

Humans

Lung Neoplasms - drug therapy

Lung Neoplasms - enzymology

Protein Kinase Inhibitors - administration & dosage

Pyrazoles - administration & dosage

Pyridines - administration & dosage

Randomized Controlled Trials as Topic - methods

Receptor Protein-Tyrosine Kinases - antagonists & inhibitors

Receptor Protein-Tyrosine Kinases - genetics

Receptor Protein-Tyrosine Kinases - metabolism

Details

Title: Subtitle: Targeted therapy for NSCLC: ALK inhibition
Creators: Rachel Pearson - University of Wisconsin–Madison
Jill M Kolesar - University of Wisconsin Carbone Cancer Center
Resource Type: Journal article
Publication Details: Journal of oncology pharmacy practice, Vol.18(2), pp.271-274
DOI: 10.1177/1078155211417477
PMID: 21844131
ISSN: 1078-1552
eISSN: 1477-092X
Language: English
Date published: 06/2012
Academic Unit: Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
Record Identifier: 9984696553602771

Metrics

2 Record Views